14.43
-0.11(-0.76%)
Currency In USD
| Previous Close | 14.54 |
| Open | 14.54 |
| Day High | 14.58 |
| Day Low | 13.81 |
| 52-Week High | 21.48 |
| 52-Week Low | 3.25 |
| Volume | 748,774 |
| Average Volume | 448,895 |
| Market Cap | 386.98M |
| PE | -80.17 |
| EPS | -0.18 |
| Moving Average 50 Days | 16.42 |
| Moving Average 200 Days | 13.49 |
| Change | -0.11 |
If you invested $1000 in Eton Pharmaceuticals, Inc. (ETON) since IPO date, it would be worth $2,308.8 as of July 16, 2025 at a share price of $14.43. Whereas If you bought $1000 worth of Eton Pharmaceuticals, Inc. (ETON) shares 5 years ago, it would be worth $2,697.2 as of July 16, 2025 at a share price of $14.43.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
GlobeNewswire Inc.
Jul 08, 2025 10:50 AM GMT
- NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceut
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
GlobeNewswire Inc.
Jun 27, 2025 10:50 AM GMT
DEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution
GlobeNewswire Inc.
May 28, 2025 9:28 PM GMT
• KHINDIVI is the first and only FDA-approved hydrocortisone oral solution• Commercial launch expected the week of June 2nd• Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE® (hydrocortisone) oral granules to exceed $50 million DEER